Extended Storage of Autologous Apheresis Platelets (Plts) in Plasma and Plasmalyte.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2108-2108 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
Esther Pellham ◽  
...  

Abstract Abstract 2108 Poster Board II-85 Background: The FDA has proposed that, at the end of storage, radiolabeled autologous plt recoveries and survivals should be 67% and 58% respectively, of the same donor's “fresh” plt recovery and survival results. Methods: Using 98 normal subjects, 3 different variables were evaluated to determine their effects on post-storage plt recoveries and survivals; i.e., storage solution (plasma and Plasmalyte), apheresis machine [Haemonetics MCS+ (H), Cobe Spectra (CS), or Cobe Trima (CT)], and storage bag (H, CS, or CT). Autologous plts were collected and either infused “fresh” or stored under the conditions of interest. The fresh and stored plts were alternately radiolabeled with either 51Cr or 111In prior to transfusion. Results: Plasma Storage. Both H and CS collected apheresis plts can be stored for 8 days and meet FDA requirements with no differences in post-storage plt recoveries or survivals between the 2 machines (see table). After 9 days of storage, 2 of 5 units (1 H and 1 CS) had pH's of <6.2, and these plts had recoveries of 36% and 26% and survivals of 1.1 and 0.9 days, respectively. Apheresis Machine Storage Time (Days) Storage Bag N PLATELET RECOVERY PLATELET SURVIVAL % % of “Fresh” Days % of “Fresh” Plt Storage In Plasma: H 8 H 10 52 ± 8 79 ± 16 5.3 ± 1.7 78 ± 16 CS 8 CS 10 54 ± 11 75 ± 8 4.7 ± 1.4 62 ± 22 Plt Storage In Plasmalyte: H 7 H 10 52 ± 10 ND 6.0 ± 0.9 ND CS 7 CS 15 47 ± 18* ND 4.3 ± 1.5* ND CT 7 CT 10 40 ± 15** 69 ± 21 5.0 ± 1.6** 64 ± 20 H 9 H 4 55 ± 11 82 ± 20 6.6 ± 1.2 93 ± 39 CS 9 CS 5 27 ± 16** ND 3.6 ± 1.9** ND CT 9 CT 9 32 ± 19*** 58 ± 35 3.7 ± 1.6*** 48 ± 23 CT 9 H 10 44 ± 13 78 ± 16 5.0 ± 0.7 59 ± 7 H 13 H 10 49 ± 10 73 ± 11 4.6 ± 1.0 69 ± 19 CS 13 CS 5 38 ± 10**** ND 2.6 ± 0.9**** ND CS 13 H 5 42 ± 14**** ND 4.6 ± 2.2**** ND Data reported as average ±1 S.D. * Four units had post-storage pH's of <6.0. ** One unit had a post-storage of pH <6.0. *** Two units had post-storage pH's of 6.1. One other unit had a pH of 6.0 and was not injected. **** CS apheresis plts were collected from 5 subjects, and half of the collection was stored in CS bags, and half in H bags. One collection had a pH <6.0 in both bags and was not injected. Plasmalyte Storage. For the H collections, the plts were elutriated using Plasmalyte instead of plasma, and, for the CS and CT collections, the plts were concentrated during collection and re-suspended in Plasmalyte. For all the collections, the final Plasmalyte concentration was 80% with 20% residual plasma. As shown in the table, H collected plts met FDA criteria for 13 days versus 7 days of storage for both CS (FDA criteria not directly tested) and CT collected plts. Even after 7 days of storage, H collected plts were significantly better than CS or CT collected plts with respect to survival (p=0.05), and, after 9 days of storage, H collected plts were significantly better than CS and CT collected plts for both recoveries (p=0.003) and survivals (p<0.001). Recoveries of CS collected plts were better than CT collected plts after 7 days of storage (p=0.01), but the rest of the CS and CT plt recovery and survival data at 7 and 9 days of storage were not different. To determine whether the better results achieved with H plts were because of the machine and/or the storage bag, experiments were performed storing CT or CS collected plts in H bags for 9 or 13 days, respectively. When stored in H bags versus CT bags, 9-day stored CT collected plts had better survivals (p=0.03). Again, CS collected plts stored for 13 days showed a trend for better survivals when stored in H versus CS bags. These data show that both the apheresis machine as well as the storage bag affect the results with the predominant effect being the storage bag. H bag is a ES 3049 PVC compound, and CS and CT bags are PVC with a citrate plasticizer. Low post-storage pH's were found at any storage interval for CS and CT collected plts mainly when stored in their respective bags. pH's <6.2 reduced recoveries by 29% points and survivals by 3.0 days. Therefore, all statistical comparisons between groups were adjusted for the effects of low pH. Conclusion: Apheresis plts can be stored in plasma for 8 days and meet FDA guidelines for plt viability with comparable results between machines and bags. Plt storage in Plasmalyte is effected by both the method of collection as well as the storage bag with the best results achieved with H plts stored in H bags. H plts stored in H bags meet FDA guidelines for 13 days of storage The importance of these results is that extended plt storage can be achieved by using the appropriate combination of storage solution, collection machine, and storage bag. Disclosures: Slichter: Gambro BCT: Research Funding. Off Label Use: Plasmalyte was used as a platelet storage solution.

Blood ◽  
2014 ◽  
Vol 123 (2) ◽  
pp. 271-280 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
Esther Pellham ◽  
...  

Key Points Extended apheresis platelet storage is dependent on the collection method, storage in a storage solution, and storage bag composition. The lifespan of the platelet is not intrinsic to the cell, and platelet viability is better maintained in vitro than in vivo.


Polymers ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1284 ◽  
Author(s):  
Bo Wang ◽  
Fu-hua Lin ◽  
Xiang-yang Li ◽  
Zhong-wei Zhang ◽  
Xiao-rong Xue ◽  
...  

Bacterial cellulose (BC) is a new kind of cellulose with great potential in enhancing preparation of isotactic Polypropylene (iPP) composites, which have been found with excellent performance. However, the interface compatibility between BC and iPP is poor. In this study, iPP/BC composites were prepared by solution mixing. Esterification modified BC (CO) and Maleic anhydride grafted polypropylene (MAPP) added as a compatibilizer was both used to improve the interfacial compatibility of the iPP/BC composites. The rheology and isothermal crystallization behavior of the composites was tested and discussed. The result shows that the complex viscosity and storage modulus of the composite significantly increase in the rule iPP, iPP/BC2, iPP/CO2, and M-iPP/BC3, which indicates that the compatibility of the composite increases as this rule. According to the isothermal crystallization kinetics result, the crystal growth mode of iPP was not affected by the addition of BC and the interfacial compatibility. The spherulite growth rate of the iPP/BC composite increases with increasing crystallization temperature. Especially, the value decreases as the same rule with the complex viscosity and storage modulus of the composite at the same isothermal crystallization temperature. These results suggest that the interface compatibility of iPP/BC composites is greatly improved and the interface compatibility of the M-iPP/BC3 is better than the iPP/CO2.


1998 ◽  
Vol 44 (3) ◽  
pp. 571-577 ◽  
Author(s):  
Lynley K Lewis ◽  
Mary W Smith ◽  
Timothy G Yandle ◽  
A Mark Richards ◽  
M Gary Nicholls

Abstract We describe a specific and sensitive RIA for human adrenomedullin (AM)(1–52). The detection limit and the concentration required for 50% inhibition of binding were 0.1 and 1.2 fmol/tube, respectively. Cross-reactivities with AM(1–12), AM(13–52), calcitonin gene-related peptide, amylin, and other vasoactive hormones were negligible. AM immunoreactivity in normal subjects ranged from 2.7 to 10.1 pmol/L (n = 44). We investigated factors influencing the recovery and measurement of AM in the assay. Recovery of labeled AM (&gt;80%) was markedly higher than that of unlabeled AM (56%). Immunoreactivity of exogenous AM added to plasma decreased up to 70% over four freeze–thaw cycles, whereas endogenous AM was stable. Alkali-treated casein (1 g/L) reduced adsorption of AM to surfaces and significantly increased assay precision compared with bovine serum albumin (P &lt;0.0001). HPLC separation of extracted plasma verified the presence of AM(1–52). We suggest that considerable care is needed to ensure that accurate and reproducible results are obtained from studies quantifying this peptide.


1976 ◽  
Vol 41 (3) ◽  
pp. 341-347 ◽  
Author(s):  
L. J. Bynum ◽  
J. E. Wilson ◽  
A. K. Pierce

Distribution of ventilation (V) and perfusion (Q) was studied with 133Xe in eight supine, normal subjects comparing spontaneous breathing (SB) and intermittent positive-pressure breathing (IPPB). Tidal volume, inspiratory flow, and breathing frequency measured during SB were closely matched during automatically triggered IPPB. V and Q in the lung bases (adjacent to the diaphragm) were decreased relative to other regions during SB and further diminished by IPPB at similar volumes. During IPPB, basilar V and Q improvedwhen tidal volume was increased; however; spontaneous hyperinflation resulted in significantly higher basilar V and Q than large tidal volumes delivered by IPPB. Thus, changes in lung volumes and gas exchange in the supine posture are attributable to impaired V and Q in the bases but not in dependent (posterior) regions. IPPB further reduces basilar V and Q, possibly due to loss of interdependence resulting from diminished respiratory muscle contraction. These findings may explain atelectasis during prolonged IPPB in supine patients. Although large tidal volumes improve basilar V during IPPB, spontaneous deep breaths are more effective and may prevent atelectasis better than IPPB at similar tidal volumes.


1991 ◽  
Vol 260 (6) ◽  
pp. H1929-H1934 ◽  
Author(s):  
R. C. Ashmore ◽  
D. M. Rodman ◽  
K. Sato ◽  
S. A. Webb ◽  
R. F. O'Brien ◽  
...  

We recently described the early appearance of pulmonary hypertension in the fawn-hooded rat (FHR), an animal with platelet storage pool disease also known to develop systemic hypertension at later ages. Since mediators released from aggregating platelets influence vascular tone, we hypothesized that platelet-mediated pulmonary vascular responses in FHR may be abnormal and potentially linked to the mechanism of pulmonary hypertension. To test this we examined reactivity of isolated pulmonary arteries (PA) and thoracic aortas (Ao) from young FHR with moderately severe pulmonary hypertension but normal systemic pressures. These vessels were compared with PA and Ao from control Sprague-Dawley rat (SDR). Aggregating platelets (1,000-40,000 platelets/mm3) from FHR caused dilation of SDR PA and Ao but constriction of FHR PA and Ao. Qualitatively similar responses were also observed with platelets isolated from SDR implying that abnormal responses were not simply due to the storage pool deficiency in FHR. Response to the platelet-derived endothelium-dependent vasodilator ADP was markedly impaired in FHR PA and mildly impaired in FHR Ao. Endothelium-dependent dilation to acetylcholine, but not to A23187, was mildly impaired in FHR PA while responses to both dilators were normal in FHR Ao. Endothelium-independent dilation to sodium nitroprusside was normal in both FHR PA and Ao. Constrictor sensitivity to serotonin, but not to the thromboxane A2 mimetic U-46619, was increased in FHR PA while responses to both constrictors were normal in FHR Ao. In summary, PAs from FHR with spontaneous pulmonary hypertension exhibit paradoxical constriction to both normal and storage pool deficient platelets.(ABSTRACT TRUNCATED AT 250 WORDS)


2003 ◽  
Vol 24 (1) ◽  
pp. 45-49 ◽  
Author(s):  
Fabian E. Pollo ◽  
James W. Brodsky ◽  
Stephanie J. Crenshaw ◽  
Chris Kirksey

The objective of this study was to determine in healthy individuals whether the Bledsoe Diabetic Conformer Boot reduces plantar pressures as well as a fiberglass total contact cast. Eighteen normal subjects, without any prior foot or ankle problems, were recruited for this study. Plantar pressures were measured using the Novel Pedar™ in-shoe pressure measurement system. The results of this study demonstrate that in individuals without foot deformities, the Bledsoe Diabetic Conformer Boot™ performs as well as, and in many parameters, even better than a fiberglass total contact cast with respect to reducing the forces and pressures on the plantar surface of the foot.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1979-1979 ◽  
Author(s):  
Amanda Cashen ◽  
Steven Devine ◽  
Ravi Vij ◽  
John DiPersio

Autologous stem cell transplantation is indicated for patients with HD who have primary refractory disease or who relapse after a first remission. For these patients, as for other patients undergoing autologous transplantation, the number of CD34+ cells infused is a reliable predictor of neutrophil and platelet engraftment, and doses ≥ 5 x 106 CD34+ cells/kg are associated with faster count recovery. However, among the 98 patients with HD who have undergone G-CSF-alone mobilization at our institution in the past five years, 22% did not achieve a minimum HPC collection of 2 x 106 CD34+ cells/kg in ≤ 5 apheresis procedures, and only 15% achieved a collection ≥ 5 x 106 CD34+ cells/kg. AMD3100 mobilizes HPCs by reversibly inhibiting the interaction of CXCR4 and SDF-1α. It has been shown to improve HPC mobilization in patients with multiple myeloma and non-Hodgkin’s lymphoma. Here we present results for the first ten HD patients treated with a mobilization regimen of AMD3100 + G-CSF. To date, ten patients with relapsed (8) or refractory (2) HD have been mobilized with G-CSF (10 ug/kg/d) + AMD3100 (240 ug/kg/d) beginning on day 4. Apheresis was performed 11 hours after each AMD3100 dose. The first dose of AMD3100 produced a median (range) 3.0 (1.9–5.1) fold increase in the number of circulating CD34+ cells. Six patients (60%) achieved a collection of ≥ 5 x 106 CD34+ cells/kg, and all patients collected > 2 x 106 CD34+ cells/kg (range, 3.6–9.4 x 106 CD34+ cells/kg). The median (range) number of apheresis procedures performed per patient was 2 (1–4). No grade II-IV adverse events were ascribed to AMD3100. Eight patients have been transplanted with G-CSF + AMD3100 mobilized cells. All have had prompt and stable engraftment, with median neutrophil recovery at day +9 (9–11) and median platelet recovery at day +20 (15–23). Two patients had very early engraftment, with absolute neutrophil count greater than 100 on day +7. We conclude that AMD3100 + G-CSF is a well-tolerated and effective mobilization regimen in patients with HD. All patients (100%, 95% CI 69%-100%) mobilized with AMD3100 + G-CSF achieved the minimum collection of 2 x 106 CD34+ cells/kg, and a significantly higher proportion of patients (60%, 95% CI 26%–88%) achieved the goal collection of ≥ 5 x 106 CD34+ cells/kg than did the historical controls (15%). Importantly, the median collection in the first two days of pheresis was 5.4 x 106 CD34+ cells/kg, which is significantly better than historical controls, who collected a median 3.0 x 106 CD34+ cells/kg in the first two days of pheresis (p=0.014). Our results demonstrate that the mobilization regimen of AMD3100 + G-CSF can improve the number of HPCs collected and decrease the number of days of pheresis in HD patients. This regimen will be pursued further in this patient population.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1995-1995
Author(s):  
Julie Kanter ◽  
Dk McLaughlin ◽  
J Dimitry ◽  
S. Rogers ◽  
Pj Kell ◽  
...  

Abstract Under normal physiologic conditions, platelets circulate in an inactivated state and require only minimal stimulation ensuring their immediate availability for hemostasis. Previous research has shown that during platelet pheresis and storage, platelets undergo early activation resulting in expression of the surface activation marker CD62, release of α granule contents, and a decrease in inducible activation. In addition to regulating vascular tone, nitric oxide (NO) groups in plasma may provide tonic inhibition to circulating platelets thereby preventing the inappropriate adhesion and aggregation seen in stored platelets. S-Nitrosothiols (RSNOs) may serve as a reservoir for nitric oxide (NO) in the normal circulation. We hypothesize that platelets are prematurely activated during the process of apheresis in part due to the lack of RSNOs in the microenvironment during collection and storage. Furthermore, RSNO metabolism by stored platelets is changed by the process of apheresis itself. To test this hypothesis, we monitored the activation status of platelets using CD62 flow cytometry and quantified intracellular NO content and uptake using the fluorescence probe diaminodifluorofluorescein diacetate (DAF-FM DA). Both measurements were made on freshly isolated platelets (Fl-Plts) and on apheresis platelets (A-Plts). In addition, we employed these techniques to evaluate the responsiveness of Fl-Plts and A-Plts to agonists [thrombin receptor activating peptide (TRAP), ADP, and collagen] and to NO-donating molecules after varying storage times. In preliminary studies we have found that Fl-Plts bind RSNOs and demonstrate steroselectivity in their degree of uptake. Fl-Plts incubated with L-RSNOs produce over 2-fold the fluorescence compared to Fl-Plts incubated with D-RSNOs. A-Plts lose this stereoselectivity in RSNO uptake following the collection and storage process. We have also found that A-Plts have up to a 10-fold increase in uptake of nitric oxide from RSNOs compared to Fl-Plts. This significant increase and loss of stereoselectivity in RSNO uptake in A-Plts correlates with the loss of inducible activation over storage time. These data suggest RSNO metabolism in platelets is fundamentally altered during apheresis, collection, and storage and provides a novel target with therapeutic potential for further investigation into the loss of platelet function during storage.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6601-6601 ◽  
Author(s):  
Jeffrey E. Lancet ◽  
Jorge E. Cortes ◽  
Tibor Kovacsovics ◽  
Donna Hogge ◽  
Jonathan E. Kolitz ◽  
...  

6601 Background: A Phase 2b study randomized untreated elderly AML pts to CPX-351 or 7+3. CPX-351 improved leukemia clearance (88% v 71%, <5% marrow blasts), CR+CRi rate (67% v 51%), and was particularly effective in pts with adverse karyotype and antecedent hematologic disorders (sAML). Survival following CRi is usually inferior compared to CR. CPX-351 markedly prolongs plasma drug levels and maintains the 5:1 molar ratio for optimal leukemic cell killing potentially delaying hematologic recovery among CRi patients. Consequently, we compared the characteristics and outcomes of pts achieving CR v CRi. Methods: Untreated AML pts, aged 60-75, PS= 0-2, SCr < 2.0 mg/dL, total bilirubin <2.0 mg/dL, ALT/AST <3 x ULN, and LVEF ≥50% were eligible. Pts were randomized 2:1 to receive up to 2 inductions and 2 consolidations with CPX-351 (100 u/m2; D 1, 3, 5; 90 min infusion) or 7+3 (cytarabine=100 mg/m2 and daunorubicin=60 mg/m2). Consolidation with stem cell transplantation (SCT) was permitted. The 1o endpoint was CR+CRi rate. The 7+3 control arm had only a single CRi among 21 responders. The CPX-351 arm had 15 CRi (27%) and 41 CR (73%) allowing a CR v CRi comparison to be made. Results: CR and CRi pts were balanced by age, race, and PS. The CRi group had more males (87% v 51%), more baseline WBC>20K (27% v 15%), and more adverse karyotype (40% v 27%) and sAML (47% v 29%). A smaller proportion of CRi pts received post-remission chemotherapy (47% v 73%) but had similar rates of SCT (13% v 20%). Most CRi pts had delayed platelet recovery (80%). By 1-year more CRi pts had relapsed (54% v 39%) and more had died (54% v 34%). Contributing causes included: relapsed AML (7 CRi v 10 CR pts), complications post SCT (1 CRi v 1 CR pt), chemotherapy complications (0 CRi v 2 CR pts) and unknown causes (0 CRi v 1 CR pt). The survival curves were not significantly different (p=0.39). Conclusions: More CRi patients had adverse karyotype and sAML and most (53%) received no post remission chemotherapy. Survival was not significantly different compared to CR patients but was markedly better than that of non-responders. These data suggest that CRi following CPX-351 provides clinically meaningful benefit, a finding that needs to be confirmed in a larger randomized study.


Vox Sanguinis ◽  
2004 ◽  
Vol 86 (3) ◽  
pp. 183-188 ◽  
Author(s):  
T. VandenBroeke ◽  
L. J. Dumont ◽  
S. Hunter ◽  
J. Nixon ◽  
S. Murphy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document